

Developing new methods to improve the diagnosis and treatment of glaucoma.

Prabirendra Nath Sinha

Assistant Professor, Department of Optometry, Swami Vivekananda University, Kolkata, West Bengal, India.

I. Introduction

Glaucoma is a group of eye conditions that damage the optic nerve, typically due to an increase in intraocular pressure. This can lead to vision loss and even blindness if left untreated. It is often called the “silent thief of sight” because symptoms may not be noticeable until the disease has progressed significantly. Early detection and treatment are crucial in managing glaucoma and preserving vision. Regular eye exams are essential in detecting glaucoma early, as it can often be asymptomatic in the early stages. The most common type of glaucoma, open-angle glaucoma, progresses slowly and can be managed effectively with medication, laser treatment, or surgery. However, if left untreated, the damage to the optic nerve can be irreversible. It is important for individuals at higher risk, such as those with a family history of glaucoma or certain medical conditions, to be proactive in monitoring their eye health and seeking regular check-ups with an eye care professional (1-4).

By catching glaucoma early, individuals can prevent further vision loss and preserve their quality of life. Regular eye exams are crucial in monitoring the progression of the disease and adjusting treatment plans as needed. With advancements in technology and treatment options, there is hope for those with glaucoma to maintain their vision and lead fulfilling lives. It is never too early to prioritize eye health and take proactive steps towards early detection and management of glaucoma. Scheduling regular appointments with an eye care professional is essential for those at risk for glaucoma, such as individuals over the age of 60, those with a family history

of the disease, or individuals with certain medical conditions like diabetes (5). These appointments can help catch any signs of glaucoma early on and allow for prompt treatment. By staying proactive and informed about the disease, individuals can take control of their eye health and potentially prevent vision loss. Remember, early detection is key in managing glaucoma and preserving vision for years to come. (6-8).

Current limitations in diagnosing and treating glaucoma include the fact that many people may not experience any symptoms in the early stages of the disease, making it difficult to detect without regular eye exams. Additionally, some treatment options for glaucoma, such as eye drops or surgery, may have side effects or risks that need to be carefully monitored by a healthcare professional (9-11). As research continues to advance in the field of ophthalmology, new technologies and therapies may become available to improve the diagnosis and management of glaucoma in the future. It is important for individuals at risk to stay informed about the latest developments in glaucoma treatment and to work closely with their healthcare provider to ensure the best possible outcomes for their eye health. By staying proactive and informed, individuals can take steps to protect their vision and overall eye health. Regular communication with a healthcare provider can help individuals stay ahead of any potential complications or changes in their condition (12-15). By staying informed about new advancements in treatment options, individuals can work with their healthcare provider to determine the best course of action for managing their glaucoma effectively. Together, patients and healthcare providers can work towards preserving vision and maintaining optimal eye health for the long term.

II. Diagnostic methods

Traditional methods (tonometry, visual field testing), as well as newer technologies such as optical coherence tomography (OCT) and retinal nerve fibre layer analysis, can provide valuable information for monitoring and managing glaucoma. These diagnostic tools help healthcare providers track progression of the disease and make informed decisions about treatment plans. By utilizing a combination

of traditional and advanced diagnostic methods, patients can receive personalized care that addresses their specific needs and helps them maintain good eye health. Regular screenings and check-ups are essential for catching any changes early and preventing further vision loss. Additionally, regular monitoring with OCT and retinal nerve fibre layer analysis can help detect subtle changes in the eye that may not be noticeable to the patient. This early detection allows for prompt intervention and adjustments to treatment plans, ultimately improving outcomes for individuals with glaucoma. By staying proactive with their eye health, patients can work closely with their healthcare providers to preserve their vision and overall quality of life (16-18). It is crucial for individuals with glaucoma to prioritize regular eye exams and follow-up appointments to ensure optimal management of their condition.

Advantages and limitations of current diagnostic tools

While current diagnostic tools have made great strides in detecting subtle changes in the eye that can indicate glaucoma progression, there are still limitations to be aware of. Some tools may not be able to detect early stage glaucoma or may produce false positives, leading to unnecessary worry and testing. Additionally, access to certain diagnostic tools may be limited in some areas, making it difficult for all individuals with glaucoma to receive the necessary monitoring and care. Despite these limitations, advancements in technology continue to improve the accuracy and accessibility of diagnostic tools for glaucoma, providing hope for better outcomes for patients in the future (19-21). Overall, while there are still challenges in detecting and monitoring glaucoma progression, the advancements in technology are promising for the future of glaucoma care. With continued research and development, it is likely that more accurate and accessible diagnostic tools will be available to patients worldwide. Through increased awareness and access to these tools, individuals with glaucoma will have a better chance at early detection and successful management of their condition. The ongoing improvements in diagnostic technology bring hope for improved outcomes and quality of life for patients with glaucoma in the years to come (22-24).

Emerging technologies (optical coherence tomography, genetic testing), as well as advancements in artificial intelligence, are revolutionizing the way glaucoma is diagnosed and treated. These technologies have the potential to not only detect the disease earlier, but also personalize treatment plans based on individual genetic factors. As a result, patients may experience better outcomes and a higher quality of life, ultimately leading to a brighter future for those living with glaucoma (25).

With these advancements, researchers and healthcare professionals are optimistic about the possibility of finding a cure for glaucoma in the near future. By utilising cutting-edge technology and personalised treatment strategies, the medical community is working towards ensuring that individuals with glaucoma can lead full and healthy lives. As more progress is made in this field, there is a growing sense of hope that one day, glaucoma may no longer be a leading cause of blindness worldwide (26-28).

III. Treatment options

Medication (eye drops, oral medications), laser therapy, and surgical procedures are currently available to help manage glaucoma and prevent further vision loss. These treatments aim to reduce intraocular pressure, which is a major risk factor for the progression of the disease. By closely monitoring patients and adjusting treatment plans as needed, healthcare providers can help individuals with glaucoma maintain their vision and quality of life (29). With ongoing research and advancements in treatment options, there is great potential for improving outcomes and ultimately finding a cure for this sight-threatening condition. Patients with glaucoma should work closely with their healthcare providers to determine the best treatment plan for their specific needs. Regular eye exams and monitoring of intraocular pressure are essential for managing the disease effectively. By staying informed about the latest treatment options and participating in clinical trials, individuals with glaucoma can be actively involved in their care and contribute to advancements in the field. With early detection and proactive management, the prognosis for individuals with glaucoma is improving, offering hope for a

future where vision loss from this condition can be prevented (30-35).

Surgical interventions (laser therapy, trabeculectomy), and medication management are also important components of treating glaucoma. These interventions can help to lower intraocular pressure and slow the progression of the disease. It is crucial for individuals with glaucoma to work closely with their eye care provider to determine the most appropriate treatment plan for their specific situation. By following their provider's recommendations and staying diligent with their eye care routine, individuals with glaucoma can help preserve their vision and maintain a good quality of life (36-38).

Regular follow-up appointments with their eye care provider are essential to monitor the effectiveness of treatment and make any necessary adjustments. In some cases, additional procedures or changes in medication may be required to manage the condition effectively. It is important for individuals with glaucoma to be proactive in their care and communicate any changes or concerns to their provider promptly. With proper management and ongoing support, individuals with glaucoma can continue to lead fulfilling and independent lives (39-41).

Potential future treatments (gene therapy, stem cell therapy) hold promise for further improving the outcomes for individuals with glaucoma. Research in these areas is ongoing, and advancements in technology and medical knowledge may provide even more effective options for managing the condition in the future (42,43). By staying informed about new developments and discussing these possibilities with their eye care provider, individuals with glaucoma can be proactive in exploring potential future treatments that may offer additional benefits for their eye health. By taking a proactive approach and staying informed, individuals with glaucoma can continue to receive the best possible care and support for their condition (44-46).

This proactive approach may also involve making lifestyle changes, such as maintaining a healthy diet, exercising regularly, and managing stress levels, which can help

to support overall eye health and potentially slow the progression of glaucoma (47, 48). Additionally, regular eye exams and monitoring of intraocular pressure are essential for early detection and treatment of any changes in the condition. By working closely with their eye care provider and following recommended treatment plans, individuals with glaucoma can better manage their condition and preserve their vision for the long term. It is important for individuals with glaucoma to be proactive and engaged in their eye care in order to achieve the best possible outcomes and maintain their quality of life (49, 50).

IV. Challenges in glaucoma management include the need for consistent medication adherence, as well as the potential for side effects from certain treatments. In some cases, surgical intervention may be necessary to control intraocular pressure and prevent further vision loss. Managing glaucoma can also be complicated by other underlying health conditions, such as diabetes or high blood pressure, which may impact the effectiveness of treatment (51, 52). Despite these challenges, with proper management and regular monitoring, individuals with glaucoma can continue to lead fulfilling and independent lives.

Compliance issues with medication can be addressed through education and support from healthcare providers. It is important for patients to understand the importance of taking their medication as prescribed to prevent progression of the disease. Regular follow-up appointments with an ophthalmologist are crucial to monitor the effectiveness of treatment and make adjustments as needed. By working closely with their healthcare team and staying proactive in their care, individuals with glaucoma can maintain their vision and overall quality of life (53).

Surgical complications and risks should also be discussed with patients considering surgical treatment for glaucoma. It is essential for patients to be fully informed about the potential risks and benefits of any surgical procedure before making a decision. Close communication with their healthcare team throughout the surgical process can help mitigate any complications and ensure a successful outcome. Patients

should feel empowered to ask questions and seek clarification on any concerns they may have about their treatment plan. With proper education and support, individuals with glaucoma can make informed decisions about their care and work towards preserving their vision for the long term (54).

Access to specialized care in underserved populations is crucial in ensuring that all individuals, regardless of their background or location, have the opportunity to receive the necessary treatment for glaucoma (55). By increasing access to specialized care in underserved populations, we can help improve outcomes and reduce the risk of vision loss in those who may not have had the resources or support to seek treatment otherwise. It is essential that healthcare systems prioritize equity and accessibility in order to effectively address the needs of all patients, especially those with chronic conditions like glaucoma (56-58).

V. Future directions

Personalized medicine approaches may also play a significant role in improving the treatment of glaucoma. By tailoring treatments to each individual's unique genetic makeup and medical history, healthcare providers can optimize outcomes and minimize side effects. Additionally, advancements in telemedicine technology could further expand access to care for those in remote or underserved areas. Collaborating with community organizations and implementing outreach programs can also help raise awareness about glaucoma and encourage early detection and treatment (59-61). Ultimately, by continuing to prioritize equity and accessibility in healthcare, we can work towards ensuring that all individuals have the opportunity to receive the care they need to preserve their vision and overall health. By working together to address barriers to care and increase education about glaucoma, we can make significant strides in preventing vision loss and improving quality of life for individuals at risk. Through a combination of technological innovation, community engagement, and proactive outreach efforts, we can bridge gaps in healthcare access and empower individuals to take control of their eye health. With a collective commitment to equity and accessibility, we can create a world where

everyone has the chance to maintain their vision and live their best life (62-65).

Integration of technology in monitoring and management of glaucoma can revolutionize the way we detect and treat the condition, making it easier for individuals to track their eye health and adhere to treatment plans. By leveraging telemedicine and digital tools, we can provide remote monitoring and personalized care to patients, especially those in underserved communities. This proactive approach not only improves patient outcomes but also reduces the burden on healthcare systems, ultimately leading to better overall eye health for everyone (66-68).

Collaboration between researchers, clinicians, and industry leaders is essential to further develop and refine these technological advancements. By working together, they can ensure that these tools are user-friendly, effective, and accessible to all individuals who need them. Additionally, ongoing research and innovation in this field will help to continuously improve the quality of care provided to patients with glaucoma, ultimately leading to better vision outcomes and quality of life for those affected by the condition. Together, we can make significant strides in the fight against glaucoma and help to preserve vision for millions of people worldwide. (68-70).

Conclusion

In conclusion, collaboration between researchers, developers, and healthcare professionals is crucial in advancing the treatment and management of glaucoma. By continuing to innovate and refine technological tools, we can make a real difference in the lives of those affected by the condition. Through ongoing research and dedication to improving patient care, we can work towards a future where vision loss from glaucoma is minimized, and individuals can enjoy a better quality of life. Together, we have the power to make a significant impact in the fight against glaucoma and preserve vision for millions around the world.

-Collaboration between researchers, developers, and healthcare professionals is essential for advancing glaucoma

treatment. By continually improving technological tools and dedicating ourselves to patient care, we can work towards minimizing vision loss and improving quality of life for those with glaucoma. Together, we have the power to make a significant impact in the fight against this condition and preserve vision for millions worldwide.

Ongoing research plays a crucial role in improving glaucoma diagnosis and treatment. By staying up-to-date on the latest advancements in the field, healthcare professionals can provide patients with more accurate diagnoses and personalized treatment plans. Research also helps to identify new therapies and interventions that can slow the progression of the disease and ultimately preserve vision. With a commitment to ongoing research, we can continue to make strides in the fight against glaucoma and improve outcomes for patients worldwide.

Potential impact on patient outcomes and quality of life

By understanding the latest research findings, healthcare professionals can tailor their approach to each individual patient, leading to better outcomes and improved quality of life. Through ongoing research, new technologies and treatment options can be developed to address the specific needs of patients with glaucoma. This dedication to advancing knowledge and treatment options will ultimately lead to better management of the disease and a higher standard of care for those affected by glaucoma.

Reference

1. Leffler CT, Schwartz SG, Giliberti FM, et al. What was glaucoma called before the 20th century? *Ophthalmol Eye Dis.* 2015;7:21-33.
2. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. *JAMA.* 2014;311:1901-1911.
3. Jonas JB, Aung T, Bourne RR, et al. Glaucoma. *Lancet.* 2017;390:2183-2193.
4. Tian H, Li L, Song F. Study on the deformations of the lamina cribrosa during glaucoma. *Acta Biomater.* 2017;55:340-348.

5. Shoji T, Kuroda H, Suzuki M, et al. Glaucomatous changes in lamina pores shape within the lamina cribrosa using wide bandwidth, femtosecond mode-locked laser OCT. *PLoS One*. 2017;12:e0181675.
6. Erb C. Functional disorders in the chronological progression of glaucoma. *Ophthalmologie*. 2015;112:402–409.
7. Okafor K, Vinod K, Gedde SJ. Update on pigment dispersion syndrome and pigmentary glaucoma. *Curr Opin Ophthalmol*. 2017;28:154–160.
8. Miglior S, Bertuzzi F. Exfoliative glaucoma: new evidence in the pathogenesis and treatment. *Prog Brain Res*. 2015;221:233–241.
9. Chan MP, Grossi CM, Khawaja AP, et al. Associations with intraocular pressure in a large cohort: results from the UK Biobank. *Ophthalmology*. 2016;123:771–782.
10. Sales CS, Lee RY, Agadzi AK, et al. Open-angle glaucoma in Filipino and white Americans: a comparative study. *J Glaucoma*. 2014;23:246–253.
11. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. *Arch Ophthalmol*. 2002;120:1268–1279.
12. Barbosa-Breda J, Van Keer K, Abegao-Pinto L, et al. Improved discrimination between normal-tension and primary open-angle glaucoma with advanced vascular examinations - the Leuven Eye Study. *Acta Ophthalmol*. 2019;97:e50–e56.
13. Pillunat KR, Spoerl E, Jasper C, et al. Nocturnal blood pressure in primary open-angle glaucoma. *Acta Ophthalmol*. 2015;93:e621–e626.
14. Bourne RR, Taylor HR, Flaxman SR, et al. Number of people blind or visually impaired by glaucoma worldwide and in world regions 1990 - 2010: a meta-analysis. *PLoS One*. 2016;11:e0162229.
15. Bourne RRA, Jonas JB, Bron AM, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projections. *Br J Ophthalmol*. 2018;102:575–585.

16. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology*. 2014;121:2081–2090.
17. Höhn R, Nickels S, Schuster AK, et al. Prevalence of glaucoma in Germany: results from the Gutenberg Health Study. *Graefes Arch Clin Exp Ophthalmol*. 2018;256:1695–1702.
18. Schuster AK, Pfeiffer N, Nickels S, et al. Steeper iris conicity is related to a shallower anterior chamber: The Gutenberg Health Study. *J Ophthalmol*. 2017;2017 2190347.
19. Kapetanakis VV, Chan MP, Foster PJ, et al. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis. *Br J Ophthalmol*. 2016;100:86–93.
20. Marx-Gross S, Laubert-Reh D, Schneider A, et al. The prevalence of glaucoma in young people. *Dtsch Arztebl Int*. 2017;114:204–210.
21. Ramdas WD, Wolfs RC, Hofman A, et al. Ocular perfusion pressure and the incidence of glaucoma: real effect or artifact? The Rotterdam Study. *Invest Ophthalmol Vis Sci*. 2011;52:6875–6881.
22. Ekstrom C. Risk factors for incident open-angle glaucoma: a population-based 20-year follow-up study. *Acta Ophthalmol*. 2012;90:316–321.
23. Le A, Mukesh BN, McCarty CA, et al. Risk factors associated with the incidence of open-angle glaucoma: the visual impairment project. *Invest Ophthalmol Vis Sci*. 2003;44:3783–3789.
24. Cudowska MA, Ramdas WD, Wolfs RC, et al. Incidence of glaucomatous visual field loss: a ten-year follow-up from the Rotterdam Study. *Ophthalmology*. 2010;117:1705–1712.
25. Nagaoka N, Jonas JB, Morohoshi K, et al. Glaucomatous-type optic discs in high myopia. *PLoS One*. 2015;10 e0138825.
26. Wang X, Rumpel H, Lim WE, et al. Finite element analysis predicts large optic nerve head strains during horizontal eye movements. *Invest Ophthalmol Vis Sci*. 2016;57:2452–2462.

27. Jonas JB, Wang N, Yang D, et al. Facts and myths of cerebrospinal fluid pressure for the physiology of the eye. *Prog Retin Eye Res.* 2015;46:67–83.

28. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. *Arch Ophthalmol.* 2002;120:701–713. discussion 829-30.

29. Zhao D, Cho J, Kim MH, et al. The association of blood pressure and primary open-angle glaucoma: a meta-analysis. *Am J Ophthalmol.* 2014;158:615–627e9.

30. Zhou M, Wang W, Huang W, et al. Diabetes mellitus as a risk factor for open-angle glaucoma: a systematic review and meta-analysis. *PLoS One.* 2014;9 e102972.

31. Shi Y, Liu P, Guan J, et al. Association between glaucoma and obstructive sleep apnea syndrome: a meta-analysis and systematic review. *PLoS One.* 2015;10 e0115625.

32. Jonas JB, Holbach L. Central corneal thickness and thickness of the lamina cribrosa in human eyes. *Invest Ophthalmol Vis Sci.* 2005;46:1275–1279.

33. Goldmann H, Schmidt T. Applanation tonometry. *Ophthalmologica.* 1957;134:221–242.

34. Harper CL, Boulton ME, Bennett D, et al. Diurnal variations in human corneal thickness. *Br J Ophthalmol.* 1996;80:1068–1072.

35. Hoffmann EM, Prokosch-Willing V. Primary open angle glaucoma. *Klin Monbl Augenheilkd.* 2017;234:1407–1422.

36. Crabb DP, Smith ND, Glen FC, et al. How does glaucoma look?: Patient perception of visual field loss. *Ophthalmology.* 2013;120:1120–1126.

37. Kim KE, Kim MJ, Park KH, et al. Prevalence, awareness, and risk factors of primary open-angle glaucoma: Korea National Health and Nutrition Examination Survey 2008–2011. *Ophthalmology.* 2016;123:532–541.

38. Heijl A, Bengtsson B, Oskarsdottir SE. Prevalence and severity of undetected manifest glaucoma: results from the early manifest glaucoma trial screening. *Ophthalmology.* 2013;120:1541–1545.

39. Gramer G, Gramer E. Stage of visual field loss and age at diagnosis in 1988 patients with different glaucomas: implications for glaucoma screening and driving ability. *Int Ophthalmol*. 2018;38:429–441.

40. Berufsverband der Augenärzte Deutschlands e. V., Deutsche Ophthalmologische Gesellschaft e. V. Leitlinie Nr. 15 c: Detektion des primären Offenwinkelglaukoms (POWG): *Glaukom-Screening von Risikogruppen, Glaukomverdacht, Glaukomdiagnose*. 2006

41. Vessani RM, Moritz R, Batis L, et al. Comparison of quantitative imaging devices and subjective optic nerve head assessment by general ophthalmologists to differentiate normal from glaucomatous eyes. *J Glaucoma*. 2009;18:253–261.

42. Abrams LS, Scott IU, Spaeth GL, et al. Agreement among optometrists, ophthalmologists, and residents in evaluating the optic disc for glaucoma. *Ophthalmology*. 1994;101:1662–1667.

43. Jonas JB, Budde WM, Panda-Jonas S. Ophthalmoscopic evaluation of the optic nerve head. *Surv Ophthalmol*. 1999;43:293–320.

44. Jonas JB, Budde WM. Diagnosis and pathogenesis of glaucomatous optic neuropathy: morphological aspects. *Prog Retin Eye Res*. 2000;19:1–40.

45. Berufsverband der Augenärzte Deutschlands e. V., Deutsche Ophthalmologische Gesellschaft e. V. Leitlinie Nr. 15 a: Primäres chronisches Offenwinkelglaukom, Normaldruckglaukom und okuläre Hypertension. 2006

46. Hoffmann EM, Miglior S, Zeyen T, et al. The Heidelberg retina tomograph ancillary study to the European Glaucoma Prevention Study: study design and baseline factors. *Acta Ophthalmol*. 2013;91:e612–e619.

47. Enders P, Adler W, Kiessling D, et al. Evaluation of two-dimensional Bruch's membrane opening minimum rim area for glaucoma diagnostics in a large patient cohort. *Acta Ophthalmol*. 2019;97:60–67.

48. Shin JW, Sung KR, Lee GC, et al. Ganglion cell-inner plexiform layer change detected by optical coherence tomography indicates progression in advanced glaucoma. *Ophthalmology*. 2017;124:1466–1474.

49. European Glaucoma Society. Terminology and guidelines for glaucoma. *PubliComm*. 2014;(4)
50. Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. *Lancet*. 2015;385:1295–1304.
51. Maier PC, Funk J, Schwarzer G, et al. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. *BMJ*. 2005;331
52. Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis. *Ophthalmology*. 2016;123:129–140.
53. Gulati V, Fan S, Gardner BJ, et al. Mechanism of action of selective laser trabeculoplasty and predictors of response. *Invest Ophthalmol Vis Sci*. 2017;58:1462–1468.
54. Lavia C, Dallorto L, Maule M, et al. Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: asystematic review and meta-analysis. *PLoS One*. 2017;12 e0183142.
55. Gedde SJ, Feuer WJ, Shi W, et al. Treatment outcomes in the primary tube versus trabeculectomy study after 1 year of follow-up. *Ophthalmology*. 2018;125:650–663.
56. Vass C, Hirn C, Sycha T, et al. Medical interventions for primary open angle glaucoma and ocular hypertension. *Cochrane Database Syst Rev*. 2007 Cd003167.
57. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. *Surv Ophthalmol*. 2008;53(Suppl 1):93–105.
58. Fudenberg SJ, Batiste C, Katz LJ. Efficacy, safety, and current applications of brimonidine. *Expert Opin Drug Saf*. 2008;7:795–799.
59. Frech S, Kreft D, Guthoff RF, et al. Pharmacoepidemiological assessment of adherence and influencing co-factors among primary open-angle glaucoma patients- an observational cohort study. *PLoS One*. 2018;13 e0191185.

60. Rouland JF, Traverso CE, Stalmans I, et al. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. *Br J Ophthalmol*. 2013;97:196–200.
61. Aquino MC, Barton K, Tan AM, et al. Micropulse versus continuous wave transscleral diode cyclophotocoagulation in refractory glaucoma: a randomized exploratory study. *Clin Exp Ophthalmol*. 2015;43:40–46.
62. Michelessi M, Bicket AK, Lindsley K. Cyclodestructive procedures for non-refractory glaucoma. *Cochrane Database Syst Rev*. 2018;4 Cd009313.
63. Malvankar-Mehta MS, Iordanous Y, Chen YN, et al. iStent with phacoemulsification versus phacoemulsification alone for patients with glaucoma and cataract: a meta-analysis. *PLoS One*. 2015;10 e0131770.
64. Pillunat LE, Erb C, Junemann AG, et al. Micro-invasive glaucoma surgery (MIGS): a review of surgical procedures using stents. *Clin Ophthalmol*. 2017;11:1583–1600.
65. Agrawal P, Bradshaw SE. Systematic literature review of clinical and economic outcomes of micro-invasive glaucoma surgery (MIGS) in primary open-angle glaucoma. *Ophthalmol Ther*. 2018;7:49–73.
66. Cabourne E, Clarke JC, Schlottmann PG, et al. Mitomycin C versus 5-Fluorouracil for wound healing in glaucoma surgery. *Cochrane Database Syst Rev*. 2015 Cd006259.
67. Ederer F, Gaasterland DA, Dally LG, et al. The advanced glaucoma intervention study (AGIS): 13 comparison of treatment outcomes within race: 10-year results. *Ophthalmology*. 2004;111:651–664.
68. Eldaly MA, Bunce C, Elsheikha OZ, et al. Non-penetrating filtration surgery versus trabeculectomy for open-angle glaucoma. *Cochrane Database Syst Rev*. 2014 Cd007059.
69. Azuara-Blanco A, Burr J, Ramsay C, et al. Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial. *Lancet*. 2016;388:1389–1397.

70. Lowe RF. Primary angle-closure glaucoma Prevention and early treatment. *Isr J Med Sci.* 1972;8:1362–1365.